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Background: Depression accounts for the greatest disease burden of all mental health disorders, contributes heavily to
healthcare costs, and by 2020 is set to become the second largest cause of global disability. Although 10% to 16% of
people aged 65 years and over are likely to experience depressive symptoms, the condition is under-diagnosed and
often inadequately treated in primary care. Later-life depression is associated with chronic illness and disability, cognitive
impairment and social isolation. With a progressively ageing population it becomes increasingly important to refine
strategies to identity and manage depression in older people. Currently, management may be limited to the prescription
of antidepressants where there may be poor concordance; older people may lack awareness of psychosocial interventions
and general practitioners may neglect to offer this treatment option.
Methods/design: CASPER Plus is a multi-centre, randomised controlled trial of a collaborative care intervention for
individuals aged 65 years and over experiencing moderate to severe depression. Selected practices in the North of
England identify potentially eligible patients and invite them to participate in the study. A diagnostic interview is
carried out and participants with major depressive disorder are randomised to either collaborative care or usual care.
The recruitment target is 450 participants.
The intervention, behavioural activation and medication management in a collaborative care framework, has been
adapted to meet the complex needs of older people. It is delivered over eight to 10 weekly sessions by a case manager
liaising with general practitioners.
The trial aims to evaluate the clinical and cost effectiveness of collaborative care in addition to usual GP care
versus usual GP care alone. The primary clinical outcome, depression severity, will be measured with the
Patient Health Questionnaire-9 (PHQ-9) at baseline, 4, 12 and 18 months. Cost effectiveness analysis will
assess health-related quality of life using the SF-12 and EQ-5D and will examine cost-consequences of
collaborative care.
A qualitative process evaluation will be undertaken to explore acceptability, gauge the extent to which the
intervention is implemented and to explore sustainability beyond the clinical trial.
Discussion: Results will add to existing evidence and a positive outcome may lead to the commissioning of this
model of service in primary care.
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Problem to be addressed
Depression accounts for the greatest burden of disease
among all mental health problems and is expected to
become the second-highest of all general health prob-
lems by 2020 [1]. Depression is common among older
people and people with co-morbid chronic medical
conditions and cognitive impairment, and can result in
poor quality of life [2]. Although 10% to 16% of people
aged over 65 years may experience depressive symp-
toms, with 2% to 4% meeting formal diagnostic criteria
for moderate to severe depression, [3] the condition is
under-diagnosed and often inadequately treated in pri-
mary care [4].
Older people with a long-term condition are five times
more likely to suffer depression. For example, 50% of
people with Parkinson’s disease will suffer depression,
25% following stroke and 20% with coronary heart dis-
ease, 24% with neurological disease and 42% with
chronic lung disease [2]. Beyond personal suffering and
family disruption, depression worsens the outcomes of
many medical disorders and promotes disability [2].
The impairments in quality of life associated with
depression are comparable to those of major physical
illness and among older people a clinical diagnosis of
major depression is the strongest predictor for im-
paired quality of life (QoL) [5]. Demographic projec-
tions indicate a growing ageing population which calls
for effective strategies to specifically tackle depression
in older people [6]. However, an important factor
noted by current and previous studies [7-9] is the
complex nature of identifying and treating depression
in an ageing population.The need for a trial
Management of depression in older people
The vast majority of depression in older people can be
managed entirely in primary care, without recourse to
specialist mental health services [10-12]. A range of indi-
vidual treatments has been shown to be effective in older
people, including anti-depressants and psychosocial in-
terventions [10], but a repeated observation among all
trials of people with depression has been the failure to
integrate these effective elements of care into routine
primary care services [13].Current NICE guidelines recommend a stepped care
framework for the management of depression. Essen-
tially, in stepped care, the ‘least intrusive, most effective
intervention’ is provided first; if this is not beneficial, or
if it is declined, patients should be offered an interven-
tion from the next step [14].
However, in the UK, depression in older people is
under-diagnosed and under-treated [15]. Even when
recognised, the provision of psychosocial interventions
for this age group is inadequate. For example, there has
been minimal provision of psychological treatment for
older people under the Improving Access to Psychological
Therapies (IAPT) programme [16].
Despite GPs being encouraged through the Quality
and Outcomes Framework (QOF) to case-find for de-
pression in older people, there is little evidence that this
has translated into better management or identification
for this disorder [11]. This indicator in the QOF frame-
work has now been removed.Collaborative care for older adults
Collaborative care is a complex intervention delivered in
primary care, based on chronic disease management
models used for conditions including diabetes. This
model of care, also referred to as case management, fa-
cilitates the delivery of effective forms of treatment (such
as pharmacotherapy and/or brief psychological therapy)
[17]. A widely-accepted definition established by Gunn
[18] states that collaborative care incorporates four re-
lated criteria: a multi-professional approach to patient
care; a structured management plan; scheduled patient
follow-ups; and enhanced communication between
professionals.
There is evidence demonstrating the effectiveness of
collaborative care with behavioural activation in improv-
ing treatment of depression for adults over 60 in the
United States [7,19] and a US systematic review of 37
randomised trials comparing collaborative care interven-
tions with usual care reported significant improvements
of the quality of depression care and patient outcomes,
lasting up to 2 to 5 years, along with increased medica-
tion adherence and improved satisfaction among pa-
tients and primary care physicians [20]. However, the
transferability of this model of care to the UK NHS can-
not be assumed and requires independent evaluation.
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fectiveness of collaborative care for depression in the UK.
In 2013 a UK trial of collaborative care for a general adult
population (CADET) reported evidence of persistent posi-
tive effects on symptoms of moderate to severe depression
among adults aged 18 years and over, up to 12 months
after the start of the intervention. However, this trial did
not collect specific data on older people [8]. The CASPER
Plus trial intervention has been developed specifically for
older people and, by increasing follow up to 18 months,
aims to extend the evidence base for this population.
Despite recent investment under the Improving Access
to Psychological Therapies (IAPT) initiative, the capacity
for specialist mental health services to provide collabora-
tive care is constrained and demand would quite quickly
outstrip supply. Hence any feasible strategy will be both
low intensity and offered within primary care [21,22].
The ubiquity of depression in primary care settings and
the poor integration and/or co-ordination of care have
led to strategies to re-engineer the delivery of care.
In a BMJ editorial (2004) on the management of depres-
sion in older people Chew-Graham notes ‘Innovations in
the management of depression have been evaluated. The
best results come from models that use multifaceted inter-
ventions and principles of collaborative care’ [6].
In our own trials of collaborative care in working age
adults, we have shown positive outcomes through the
combination of medication management and a low in-
tensity psychological intervention, ‘behavioural activa-
tion’ (BA), which can be readily delivered in eight to 10
sessions by a trained case manager either over the phone
or face to face for those who have difficulty using or
accessing phone-based therapy [23]. Briefly, behavioural
activation focuses on the behavioural deficits common
among those with depression, it reintroduces positive
reinforcement and reduces avoidance. The effectiveness of
BA is now well demonstrated in trials and has been shown
to be at least as effective as more complex forms of psy-
chological intervention such as cognitive behavioural ther-
apy [24]. Several trials have shown positive results in older
adult populations and the focus on self-enhancement and
physical activity is especially relevant [25].
The CASPER plus trial
CASPER Plus is a multi-centre, randomised controlled
trial of a collaborative care intervention for individuals
aged 65 years and over experiencing moderate to severe
depression. For a detailed description see Table 1 ‘The
SPIRIT checklist’.
Research objectives
1. To establish the clinical effectiveness of a
collaborative care intervention for older people withscreen-positive above-threshold (‘major depressive
disorder’) depression within a definitive RCT.
2. To examine the cost effectiveness of a collaborative
care intervention for older people with screen-
positive above-threshold (‘major depressive dis-
order’) depression within a definitive RCT.
Methods/design
The CASPER Plus trial aims to evaluate the clinical and
cost effectiveness of collaborative care in addition to
usual GP care versus usual GP care alone. The trial is
designed as a multi-centre, un-blinded, pragmatic [26],
randomised controlled trial lasting 42 months, compris-
ing an 18-month definitive trial, an 18-month follow-up
phase, followed by 6 months for analysis and final re-
port. Ethical approval from the National Health Service
Research Ethics Committee (NHS REC) has been ob-
tained from Leeds East REC (reference 10/H1306/61)
and local approvals have been gained through local NHS
R & D offices: Leeds PCT, North Yorkshire & York PCT;
East Riding of Yorkshire PCT; Newcastle PCT and Hull
Teaching PCT; County Durham and Tees Valley PCT;
Northumberland Care Trust; Northumberland Tyne and
Wear NHS Trust.
Study design
The trial is a sub study to the wider CASPER study [27]
which commenced in 2011 and has successfully re-
cruited an epidemiological cohort of people aged 65 years
and over (the CASPER cohort) identifying those eligible
to participate in a trial of collaborative care for sub-
threshold depression (the CASPER trial). As part of a
simultaneous recruitment process, the CASPER Plus
trial will identify participants with major depressive dis-
order. A flowchart of the CASPER study, outlining this
process, is detailed in Figure 1.
CASPER plus trial recruitment
Recruitment of practices
GP practices will be recruited following introductions by
the local PCRN. Practices will be paid a set fee by the
CLRN for conducting a search of patients who meet the
inclusion and exclusion criteria, plus a further reim-
bursement for each person invited and for the collection
of objective data at the end of the trial.
Participant recruitment
Participants will be recruited from four main recruit-
ment centres in the North of England: York (the trial
centre), Leeds, Durham, Newcastle and their surround-
ing areas. Participants to the CASPER Plus trial are
identified via GP practices. Informed consent will be
gained from each participant.
Table 1 The SPIRIT checklist
Data category Information
Primary registry and trial
identifying number
ISRCTN 45842879
Date of registration in primary
registry
24 July 2012
Secondary identifying numbers HTA - Project: 10/57/43 CASPER Plus
Source of monetary of material
support
National Institute of Health Research Health Technology Assessment (NIHR HTA)
Primary sponsor University of York
Contact for scientific and/or
public queries
Professor Simon Gilbody 01904 430000 (simon.gilbody@york.ac.uk)
Public title The CASPER Plus study
Scientific title Collaborative Care for Screen-Positive Elders with major depressive disorder
Countries of recruitment UK
Health condition(s) or problem(s)
studied
Depression in older people
Intervention(s) Behavioural activation (BA) and medication management delivered in a collaborative care framework by a case
manager liaising with general practitioners/health professionals/third sector, with supervision from a mental
health specialist
Key inclusion and exclusion
criteria
Inclusion criteria: Aged 65 years and over; screen positive to at least one of the Whooley questions and who,
on further assessment with the MINI diagnostic tool and PHQ-9 questionnaire, have DSM-IV Major Depressive
Disorder (MDD). See protocol paper
Exclusion criteria: Known alcohol dependency (as recorded on GP records); any known co-morbidity that would
in the GP’s opinion make entry to the trial inadvisable (for example, recent evidence of self-harm, known current
thoughts of self-harm, significant cognitive impairment); other factors that would make an invitation to participate
in the trial inappropriate (for example, recent bereavement, terminal illness); known to be experiencing psychotic
symptoms (as recorded on GP records)
Study type Randomised controlled trial
Interventional
Allocation: randomised
Masking: none
Primary purpose: prevention and/or improvement of symptoms
Date of first recruitment 15 September 2012
Target sample size 450
Recruitment status Recruiting
Primary outcome(s) Depression severity at 4 months (following intervention) by self-report using the Patient Health Questionnaire 9
(PHQ-9) on a continuous scale. We will also measure outcome at 12 and 18 months using the PHQ-9 to examine
any sustained impact of the intervention
Secondary outcome(s) Secondary outcomes include the SF-12 and GAD-7 at 4, 12 and 18 months. We will also collect data on somatic
symptom severity using the PHQ-15, participant resilience using the CD-RISC2 and cost effectiveness including
the EQ-5D, prescribed medication and health and social care use. See protocol paper for references
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of patients who consult for depression and targeted
searches in order to identify those aged 65 and over
most at risk of depression, for example, those with
chronic conditions such as diabetes, CHD and COPD.
All patients who have been identified by their GP
practice as eligible to join the study are then screened
by individual GPs before being sent an invitation
pack; if referred by their GP, patients are given the
pack at consultation. Patients who wish to take part in the
CASPER study are asked to return their completed consentand background information forms by post to the
study centre. All consenting participants are then sent
a baseline questionnaire by the research team and
asked to complete and return this. Inclusion in the
CASPER Plus trial is dependent on participants meeting
the inclusion criteria and currently experiencing major
depressive disorder.
Identifying participants with major depressive disorder
On receipt of a valid baseline questionnaire, all partici-
pants are contacted over the telephone by a trained
GP/Practice Recruitment to CASPER cmRCT
Practice database screening of all over 65s & send Patient Letter of 
Invitation
Baseline questionnaire for depression (including the ‘Whooley 
questions’, PHQ-9, SF-12 Health Economics questions)
Telephone assessment for eligibility (using the MINI, PHQ9)
Ineligible (below 
threshold)
Randomisation
4 month 
follow-up
12 month 
follow-up
Collaborative 
Care
4 month 
follow-up
12 month 
follow-up
12 month 
follow-up
Usual GP 
Care
4 month 
follow-up
DSM-IV Major 
Depressive 
Disorder
Randomisation
Collaborative 
Care
4 month follow-
up
12 month 
follow-up
12 month 
follow-up
Usual GP Care
4 month follow-
up
DSM-IV sub-
threshold 
depression
CASPER Trial – identification, recruitment & progress
CASPER Plus Trial – identification, recruitment & progress
18 month 
follow-up
18 month 
follow-up
CASPER-Plus trial
CASPER trial
The CASPER Study Design and Flowchart
Figure 1 Design and flowchart of the CASPER study.
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major depressive episode module of the Mini Inter-
national Neuropsychiatric Interview (M.I.N.I) is used to
ascertain the presence or absence of depressive symp-
toms and depressive disorders. All eligible participants
diagnosed with major depressive disorder are rando-
mised to either the intervention group: collaborativecare with behavioural activation, medication manage-
ment and active surveillance; or the control group: usual
primary care management of above-threshold depression
(major depressive episode) offered by the patient’s GP, in
line with NICE depression guidance and local service
provision [10,28] Table 2 shows the criteria for identify-
ing a major depressive episode using the DSM-IV.
Table 2 Diagnostic criteria for depression based on DSM-IV
Based on the nine-item depression module from the MINI
participants are classified in the following way:
• Major depressive episode: Five or more symptoms, including one of
the key symptoms
• Sub-threshold depressive symptoms: Two to four symptoms, may or
may not include a key symptom
• Non-depressed: None or one symptom
Symptoms:
1. Depressed mooda
2. Loss of interesta
3. Significant weight loss or gain or decrease or increase in appetite
4. Insomnia or hypersomnia
5. Psychomotor agitation or retardation
6. Fatigue or loss of energy
7. Feelings of worthlessness or excessive or inappropriate guilt
8. Diminished ability to think or concentrate, or indecisiveness
9. Recurrent thoughts of death, recurrent suicidal ideation without a
specific plan, or suicide attempt or a specific plan
aKey symptom.
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automated system through the trial database. Partici-
pants are sent a letter indicating the group to which they
have been randomly allocated; GPs are sent a similar let-
ter notifying them of their patients’ allocation.
Inclusion and exclusion criteria
Eligible participants will be identified from practice lists
at participating GP practices.
The following eligibility criteria will be used:
Inclusion criteria
 Aged 65 years and over
 Screen-positive to at least one of the Whooley
questions [29,30] listed below and who, on further
assessment with the MINI diagnostic tool and PHQ-
9 questionnaire have DSM-IV Major Depressive Dis-
order (MDD) [31,32].
The Whooley questions
1. ‘Over the past month, have you been bothered by
feeling down, depressed or hopeless?’
2. ‘Over the past month, have you been bothered by
having little interest or pleasure in doing things?
Exclusion criteria
Participants are excluded according to the GP’s discre-
tion, during screening of the patient list, using the fol-
lowing guidelines: Known alcohol dependency (as recorded on GP
records).
 Any known co-morbidity that would in the GP’s
opinion make entry to the trial inadvisable (for ex-
ample, recent evidence of self-harm, known current
thoughts of self-harm, significant cognitive
impairment).
 Other factors that would make an invitation to
participate in the trial inappropriate (for example,
recent bereavement, terminal illness).
 Known to be experiencing psychotic symptoms (as
recorded on GP records).
Trial intervention
Intervention group: collaborative care with behavioural
activation
Participants randomised into the intervention group will
receive collaborative care (including BA) with medica-
tion monitoring and management. This experimental
intervention is a bespoke collaborative care designed
and delivered specifically for those aged 65 years or over
with above threshold, case-level depression over eight to
10 weekly sessions. Participants randomised to the inter-
vention group will be contacted by the allocated case
manager to arrange their first session face to face.
Collaborative care will be delivered by a case manager
(CM: a primary care mental health worker) within a
‘stepped care framework’, such that those whose depres-
sion deteriorates are ‘stepped up’ from low intensity care
to a more intensive form of management including
medication monitoring. This will be delivered according
to an established protocol [33].
The five core components of the intervention are de-
scribed below:
(1) Patient-centred assessment and engagement:
patients are usually first assessed in their own
residential setting. The severity of depression and
associated behavioural and social deficits are
assessed. The presence of depressive symptoms and
behavioural deficits are described and patient
information materials are given.
(2) Symptom measurement and monitoring: a
standardised assessment of symptom severity is
made by symptom tracking (to judge response,
failure to respond or deterioration) using the GDS-
15, a reliable and valid measure for depressive symp-
tom severity in older adults, which is then carried
out at all subsequent patient contacts.
(3) Medication management: the prescription of anti-
depressant medication is entirely at the discretion of
the general practitioner. We will encourage GPs to
consider NICE guidance in their prescribing deci-
sions. The concordant use of medication by patients
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prescription has been initiated by the GP. Patient
concerns (such as ‘addiction’) and non-compliance
will be explored and addressed during sessions.
There will be active liaison with GPs to encourage
follow-up patient appointments with the GP if
poor adherence is noted by the CM.
(4) Active follow-up: all patients are proactively
followed up by the CM for 8 weeks using face-to-face
meetings or telephone contacts. Our own experience
is that telephone contacts are acceptable and that
patients can be engaged using this means of
communication [33]. We have adapted this means
of delivery to the specific needs of people aged
65 years and over.
(5) Delivery of Behavioural Activation (BA): patients
are offered the option of BA delivered over eight
sessions by their case manager. BA consists of a
structured programme of reducing the frequency of
negatively reinforced avoidant behaviours in parallel
with increasing the frequency of positively
reinforcing behaviours to improve functioning and
raise mood. During this time patients will remain
under the medical care of their general practitioner.
We have demonstrated that BA is potentially
effective in older adults [25] and have recently
demonstrated the effectiveness of this approach in
working age adults [34]. Following completion of the
intervention, the participant is offered a final contact
6 weeks later. This enables the participant to
consolidate new information learned and reflect on
any behavioural changes made. If during treatment
it becomes apparent that symptoms are not
improving the case manager and participant will
collaboratively discuss options for further treatment.
This may require referral back to the GP for possible
medication review or prescription or stepping up
into the local Improving Access to Psychological
Therapies (IAPT) service for interventions such as
Cognitive Behavioural Therapy or Counselling.
As part of collaborative care the GP is informed rou-
tinely by letter at the beginning, mid-point and end of
the participant’s progress. If the CM is concerned about
the participant’s mental wellbeing it may be necessary,
with the participant’s consent, to contact their GP to dis-
cuss these concerns. The only time consent may not be
required is if the participant’s life is at risk, from them-
selves or others.
The additional elements of collaborative care include:
telephone support; symptom monitoring and active surveil-
lance (facilitated by a computerised case management sys-
tem PC-MIS); medication monitoring and a low intensity
psychosocial intervention (behavioural activation). PC-MISis a web-based management information system developed
collaboratively by the Department of Health Sciences
Mental Health Research group and Health Sciences IT
Services, with the specific purpose of managing high-
volume mental health patients, through stepped care. It
allows assigned clinicians and supervisors to access partici-
pant details and their current treatments, thereby improv-
ing clinical and information governance.
Intervention manual
All CMs follow the guidance of a detailed intervention
manual, thereby optimising consistency across all the
sites. The work of CMs is overseen by an older persons’
mental health specialist (old age psychiatrist or psycholo-
gist). This is made possible by each CM being assigned a
supervisor from the principle site (University of York)
who has completed the IAPT Psychological Wellbeing
Practitioner supervisor course.
Usual care group
Participants allocated to the usual care group will receive
usual primary care management of case level depression
offered by their GP, including the prescription of any ne-
cessary medication. Participation in the trial will there-
fore not affect medication prescribing, which will remain
entirely in the control of GPs.
Case manager training
All CMs will participate in a comprehensive 3-day training
programme delivered by supervisors at the University of
York. This includes training on the use of the study spe-
cific manual, procedures, behavioural theories underpin-
ning BA, medication management and specific training on
working with older adults. This in-depth training aims to
ensure adherence and fidelity to the model. We will not
formally assess adherence and competence.
Sample size calculation
In line with the IMPACT US trial [7] and the point esti-
mate from our UK pilot trial [35], a standard effect size
of 0.35 is sought as a conservative estimate of the detect-
able difference in mean PHQ-9 [36] depression severity
scores between collaborative care and usual care. This
difference equates to approximately 1.4 PHQ-9 score
points (assumed SD = 4.1). In order to detect such a dif-
ference with 80% power at the 5% two-sided significance
level, assuming an ICC of 0.02 (case load size of 20) and
20% loss to follow-up, the sample size needed will be
450 (225 in each group).
Follow-up
Data collection will occur at six time points: at invita-
tion, baseline (pre-randomisation/pre-assessment), diag-
nostic interview for participants entering the trial, at
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tion/assessment. Additionally, primary care sources will
be checked for medication prescribing during the partic-
ipant’s time in the trial. Postal questionnaires will be
used for data collection at baseline, 4-, 12- and 18-
month follow-ups.Outcome measures
The primary outcome measure is mean depression se-
verity at 4 months by self-report using the Patient
Health Questionnaire 9 (PHQ-9) on a continuous scale.
We will also measure outcome at 12 and 18 months
using the PHQ-9 to examine any sustained impact of the
intervention.
Secondary outcomes include the SF-12 [37] and GAD-
7 [38] at 4, 12 and 18 months. We will also collect data
on somatic symptom severity using the PHQ-15 [39],
participant resilience using the CD-RISC2 and cost
effectiveness including the EQ-5D [40], prescribed medi-
cation and health and social care use. Resource utilisa-
tion and cost data will be collected to fully reflect the
management of depression and the consequential ‘total
healthcare costs’ for individuals in both collaborative
care and usual care groups, and these will be analysed
within a societal perspective.Data analysis
Statistical analysis of clinical data
We will analyse the data on an ‘intention-to-treat’ basis.
The primary outcome of depression severity is the con-
tinuous PHQ-9 depression score. Data will be analysed
by a mixed effects model to compare collaborative care
with usual care over all follow-up time points. The ana-
lysis will be adjusted for baseline depression severity
(PHQ-9 score) and physical functional limitations (SF-12
physical component score). Estimates of the mean differ-
ence between randomised groups at 4 months follow-up
will constitute the primary end point and will be pre-
sented with 95% confidence intervals. The analysis will
include all patients with valid PHQ-9 scores at any
follow-up time point and complete covariate data [30].
The number of non-responders will be calculated for
each treatment group and response rates compared. We
will undertake a secondary analysis to explore the im-
pact of missing data by including predictors of non-
response as covariates in the primary model. Analyses of
secondary outcomes will be conducted using linear or
logistic mixed models, depending on the outcome meas-
ure, adjusting for the same covariates as the primary
analysis. Variability of within-therapist clustering will be
explored by including CMs as random effects in the pri-
mary analysis. Full details will be provided in the statis-
tical analysis plan.Analysis of economic data
Economic evaluation will take the form of within-trial
cost-utility analysis to determine the incremental cost
per quality adjusted life year (QALY) for treatment
with collaborative care against usual care in individuals
with depression. Following NICE evaluation guidelines,
the primary analyses will be conducted from the per-
spective of the UK NHS and personal and social ser-
vices (PPS). The cost-effectiveness acceptability curve
(CEAC) will represent the probability that collabora-
tive care is cost-effective compared to usual care for a
range of maximum monetary values (ceiling ratios)
that a UK decision-maker may be willing to pay for an
increase in one unit of QALY. Furthermore, a net
benefit analysis will be undertaken to evaluate the net
monetary gain that can be achieved with implementa-
tion of collaborative care thus indicating to decision
makers the value of the intervention in terms of mon-
etary gain.Process evaluation
While a considerable evidence base exists for the role of
collaborative care in improving treatment of depression
in the USA, there is a recognised gap between demon-
strated efficacy in trials and implementation in everyday
practice, with particular uncertainty around whether the
model will effectively translate to UK healthcare systems.
The UK Medical Research Council has highlighted the
need for process evaluations to understand the problems
of integrating interventions into healthcare settings. A
recent trial of collaborative care in the adult population
[41] highlighted organisational barriers to embedding
the intervention into routine primary care. The process
evaluation for CASPER Plus will add to the existing lit-
erature by including data collection from patients, as
well as identifying barriers and facilitators to implemen-
tation of this model of care in the older population, who
view ‘depression’ very differently from the younger adult
population [4].
We will therefore undertake a qualitative process
evaluation to evaluate the extent to which the collabora-
tive care model was delivered and received, and how it
impacted on practices. The aims of the process evalu-
ation are to explore:
(1) Feasibility and acceptability of the collaborative care
intervention as experienced by both patients and
professionals (CMs and GPs).
(2) Likely sustainability of collaborative care models of
care beyond the trial.
The COREQ checklist, consolidated criteria for report-
ing qualitative research, is given in Table 3.
Table 3 The COREQ checklist
Item Description
Domain 1: Research team and
reflexivity
Interviewer Researchers KB and KO will conduct the interviews
Credentials of interviewers KB MSc Environmental Epidemiology and Policy
KO MA English Literature
Occupation of interviewers Researchers based in Department of Health Sciences, Seebohm Rowntree Building, University of York, Heslington,
York YO10 5DD, UK
Gender of interviewers Female
Training and experience Researchers conducting interviews have undergone basic training in qualitative methods, and will be closely
supervised and mentored by CCG/SG
Relationship with patients Researchers may have conducted a baseline interview with patients prior to qualitative interview, or may not have
met or spoken to the interview participant before
Participant knowledge of the
interviewer
The research and purpose of the interview will be explained as part of the consent process with the participant
Interviewer characteristics Interviewers conducting the qualitative study are members of the research team for the CASPER Plus study,
thus potentially biased in their view of the intervention and trial
Domain 2: Study design
Theoretical framework The qualitative exploration has some a priori assumptions; an initial thematic analysis using principles of constant
comparison will be followed by analysis using the Normalisation Process Theory [42] in order to explore how the
intervention might be incorporated into routine practice
Sampling of participants A purposive sample of patient participants will be invited to be interviewed, ensuring variation in age (65 to
79 years and 80+ years), gender, research site. We invite patients who have completed the intervention and
those who decline to participate in the trial and those who have ‘dropped out’
All CMs will be invited to be interviewed
All GPs in participating practices will be invited to be interviewed, and sampling will ensure a mix of age,
years in practice, gender, demography and size of practice
Method of approach Potential patient participants were invited by mail which included a letter, information leaflet and consent form
CMs were approached either directly or by email with information leaflet and consent form
GPs were contacted by email or letter, with attached information leaflet and consent form
Sample size Sample size of CM data set will be limited by number of CMs in the trial
Interviews with patient participants and GPs will continue until category saturation is achieved in each data set
Non-participation We will record how many potential participants who were invited declined to participate
Setting CMs and GPs will be interviewed in their place of work
Patient participants will be offered a choice of venue for the interview: home visit, GP practice, university office,
other venue of their choice
Presence of non-participants For patient participants, it is possible that spouses or carers may be present during the interviews
Domain 3: Data collection
Interview guide The interview guide will be developed by the research team with reference to their previous work, the wider
literature and through discussion of the study’s aims and objectives
Repeat interviews No repeat interviews are planned
Recording Interviews will be audio-recorded, downloaded and transcribed (anonymising the data at this point). The digital
recording will be deleted
Field notes Field notes will be kept by the interviewers, and discussed in research meetings. These notes will contribute to
modification of the interview guide and to data analysis
Duration A record of the duration of each interview will be kept
Data saturation Interviews will be conducted until data saturation is achieved in each data set
Transcripts returned We do not plan to send the transcripts to participants for comment
Domain 4: Analysis and
findings
Number of data coders
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Table 3 The COREQ checklist (Continued)
Three researchers (KO, KB, CCG) will conduct data coding, with discussion of the coding at regular research
meetings
Description of the coding tree We do not plan to publish a description of the coding tree
Derivation of themes Some of the themes will be a priori themes, anticipated from the wider literature; we anticipate that new themes
will emerge from analysis of the data, specific to this age group of patients
Software Software will not be used to organise the data
Participant checking We anticipate that there may be occasional instances when we need to re-contact the participant to clarify some
point in the transcript
Reporting - Quotations We will use illustrative data extracts to support our findings
Data consistency We will look for dis-confirmatory evidence as we conduct interviews and analysis. We will result such evidence
Clarity of major themes We will present the major themes in any publications
Clarity of minor themes We will present minor themes and dis-confirmatory evidence in our outputs, particularly in report to HTA
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Interviews will be conducted by a qualitative researcher
with all CMs, a sample of trial participants including
those who declined the intervention or dropped out,
and a sample of GPs. The interviews will be digitally-
recorded (with participant’s consent) and transcribed,
and transcripts will form the data to be analysed initially
thematically, using a constant comparison approach.
The topic guide will be modified as data collection and
analysis progresses. Data analysis will involve a process
of organising the data, descriptive coding, interpretive
coding, writing and theorising.
Comparative analysis both within and across the data
sets will be carried out to allow data from different par-
ticipants to be compared and contrasted. Deviant cases
will be actively sought throughout the analysis and
emerging ideas and themes modified in response. Data
analysis will involve at least two members of the re-
search team to independently read transcripts and dis-
cuss coding and emerging themes, supervised by CCG.
We will then reanalyse the data using the framework of
the Normalisation Process Theory [42] in order to ex-
plore the barriers and facilitators of incorporating this
intervention into routine care.
The process evaluation is an integral component of
CASPER Plus [43] and will add value to the trial in
explaining the findings and increasing the utility of the
trial results and implications for clinical practice.
Discussion
Recruiting participants from this population may prove
to be challenging and we are mindful of the need to
adapt our recruitment methods. Adjustments have been
made in our search criteria to account for the difference
in population groups, that is, older adults with major de-
pressive disorder compared to those with sub threshold
depression, and a larger invitation base will be necessary
in order to meet our recruitment target. We anticipate
that this study will add to the existing internationalknowledge base of collaborative care for depression
which has not yet been explored for an older population
in a UK setting. In our economic analysis we aim to
provide evidence of whether this intervention for older
people will be cost effective when delivered within pri-
mary care. [44] We hope results will translate success-
fully into both health policy and practice.
Patient and public involvement
In advance of recruitment to the CASPER Plus trial, a
patient and public involvement group was established.
In an effort to meet NICE guidelines for patient and
public involvement, to enable transparency and improve
relevance of the study for the public, members of this
group were asked to review and comment on the invita-
tion materials.
Trial management
The Chief Investigator, Simon Gilbody, is responsible for
the overall management of the CASPER Plus study. The
York based Trial Manager, Helen Lewis, will be respon-
sible for the co-ordination of the study between the sites.
Recruitment has been extended from two sites - originally
York (PI Simon Gilbody) and Leeds (PI John Holmes) - to
four, with the addition of Durham (PI David Ekers) and
Newcastle (PI Esther Cohen-Tovee) with the aim of meet-
ing the recruitment target for this difficult to reach group.
A trial research team in each site will carry out the day to
day activities involved in recruiting and running the trial.
Delivery of collaborative care is carried out by dedicated,
skilled and trained CMs at each site, who are specifically
trained for the trial and supervised by trial supervisors to
ensure continuity of delivery. The process evaluation will
be managed by Carolyn Chew-Graham.
A Trial Management Group oversees the operational
management of the CASPER Plus trial. Additionally, an
independent Trial Steering Committee and Data Monitor-
ing & Ethics Committee have been established; both com-
mittees meet at regular intervals to oversee the overall
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bership can be obtained from the corresponding author,
Professor Simon Gilbody.
For further information on the HTA’s projects, see:
http://www.nets.nihr.ac.uk/programmes/hta.
Trial status
The CASPER Plus trial is still in its recruitment phase.
The process evaluation has begun.
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